| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/20/2004 | US6680330 Rapamycin dialdehydes |
| 01/20/2004 | US6680326 Antitumor agents; anticancer agents |
| 01/20/2004 | US6680320 Urokinase inhibitors |
| 01/20/2004 | US6680318 Piperazinomethylbenzamides as delta-opioid receptor agonists |
| 01/20/2004 | US6680317 N-(phenyl)-n*-(2-hydroxy-3-aminosulfonylphenyl)guanidine derivatives; chemokine inhibitors; respiratory, cardiovascular, rheumatic, brain, and nervous system disorders |
| 01/20/2004 | US6680311 Cryptophycin compounds |
| 01/20/2004 | US6680309 Administering hypocalcemic hydroxyvitamin d compound having ahydrocarbon moiety at the c-24 position as anticarcinogenic agent |
| 01/20/2004 | US6680306 Method for enhancing the effectiveness of cancer therapies |
| 01/20/2004 | US6680172 Diagnosing high grade glioma by detection of tax-1 protein or polypeptide; gene expression |
| 01/20/2004 | US6680170 Polynucleotides encoding STE20-related protein kinases and methods of use |
| 01/20/2004 | US6680169 Poliovirus replicons encoding therapeutic agents and uses thereof |
| 01/20/2004 | US6679824 Products and methods for brachytherapy |
| 01/20/2004 | US6678998 Floral packaging material having great masters prints thereon |
| 01/20/2004 | CA2303498C Dioxocyclopentyl hydroxamic acids |
| 01/20/2004 | CA2243404C Bi-aromatic compounds, pharmaceutical and cosmetic compositions containing same and uses |
| 01/20/2004 | CA2174104C Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| 01/20/2004 | CA2110335C Process for producing n4-acyl-5'-deoxy-5-fluorocytidine derivatives |
| 01/20/2004 | CA2090961C Specific binding agents |
| 01/20/2004 | CA2078235C Idiotypic vaccination against b cell lymphoma |
| 01/17/2004 | CA2435399A1 New anthracene derivatives and their use as pharmaceutical preparations |
| 01/15/2004 | WO2004005549A1 Method of estimating effect of interferon |
| 01/15/2004 | WO2004005540A2 Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases |
| 01/15/2004 | WO2004005538A1 Method of screening anticancer agent |
| 01/15/2004 | WO2004005529A2 GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF |
| 01/15/2004 | WO2004005511A1 Tumor-lysing virus growing selectively in tumor cells |
| 01/15/2004 | WO2004005476A2 Nucleic acid compositions for stimulating immune responses |
| 01/15/2004 | WO2004005457A2 Tfc/ beta-catenin regulated genes for treating cancer |
| 01/15/2004 | WO2004005351A2 Neoplasm specific antibodies and uses thereof |
| 01/15/2004 | WO2004005350A2 Mutant fab fragments of the chimeric 13b8.2 anti-cd4 antibody and uses thereof |
| 01/15/2004 | WO2004005349A2 Preparation based on an antibody directed against a tumor-associated glycosylation such as lewis structures |
| 01/15/2004 | WO2004005328A2 Peptidomimetic compound useful as inhibitor of integrins |
| 01/15/2004 | WO2004005327A1 Novel tubulysin analogues |
| 01/15/2004 | WO2004005314A1 ESTRIENO[3,2-b]/[3,4-c]PYRROLE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS |
| 01/15/2004 | WO2004005313A2 Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules |
| 01/15/2004 | WO2004005311A1 Bafilomycin-like metabolite from a novel micromonospora species |
| 01/15/2004 | WO2004005304A1 Ruthenium anticancer complexes |
| 01/15/2004 | WO2004005281A1 Inhibitors of tyrosine kinases |
| 01/15/2004 | WO2004005279A2 Substituted anthranilic amide derivatives and methods of use |
| 01/15/2004 | WO2004005278A1 Bisarylsulfonamide compounds and their use in cancer therapy |
| 01/15/2004 | WO2004005277A1 Novel compunds, pharmaceutical compositions containing same, and methods of use for same |
| 01/15/2004 | WO2004005260A1 A-`7-halo-2-quino (xa-) linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents |
| 01/15/2004 | WO2004005258A1 Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| 01/15/2004 | WO2004005243A2 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives |
| 01/15/2004 | WO2004005229A1 Modulators of the glucocorticoid receptor |
| 01/15/2004 | WO2004004834A1 Compounds and methods for treating cancer and inflammation |
| 01/15/2004 | WO2004004786A1 Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
| 01/15/2004 | WO2004004784A1 A complex of tumor ablation mixture and its use in the preparing drugs for treating tumors |
| 01/15/2004 | WO2004004778A1 Use of cetp inhibitors and optionally hmg coa reductable inhibitors and/or antihypertensive agents |
| 01/15/2004 | WO2004004771A1 Immunopotentiating compositions |
| 01/15/2004 | WO2004004770A1 Chemotactic factor inhibitor for modulating inflammatory reactions |
| 01/15/2004 | WO2004004756A1 Use of pthrp antagonists for treating renal cell carcinoma |
| 01/15/2004 | WO2004004748A1 Agaricus blazei murill extract capable of preventing cancer induction or metastasis |
| 01/15/2004 | WO2004004736A1 Novel use of imidazotriazinones |
| 01/15/2004 | WO2004004733A1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives |
| 01/15/2004 | WO2004004732A1 Quinazoline derivatives for use in the treatment of cancer |
| 01/15/2004 | WO2004004729A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 01/15/2004 | WO2004004720A1 3-`(hetero) arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors |
| 01/15/2004 | WO2004004713A1 Fredericamycin derivatives as medicaments for treating tumours |
| 01/15/2004 | WO2004004711A1 Use of at least two anticancer compounds, one of which at least modulates proteasome activity for making a medicine for cancer treatment |
| 01/15/2004 | WO2004004708A1 A pharmaceutical composition useful for treating chronic myeloid leukemia |
| 01/15/2004 | WO2004004703A1 m-PHENYLENEDIAMINE DERIVATIVE |
| 01/15/2004 | WO2004004698A2 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 01/15/2004 | WO2004004665A2 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 01/15/2004 | WO2004004653A2 Methods for treating psychosis associated with interferon-alpha therapy |
| 01/15/2004 | WO2004004652A2 Mitotic kinesin binding site |
| 01/15/2004 | WO2004004651A2 Therapeutic amides |
| 01/15/2004 | WO2004004648A2 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 01/15/2004 | WO2004004641A2 PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPα SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS |
| 01/15/2004 | WO2004004633A2 Use of tnfalpha antibodies and another drug |
| 01/15/2004 | WO2004004632A2 Flavone derivatives as inhibitors of cyclin-dependent kinases |
| 01/15/2004 | WO2003094831A3 Novel diazabicyclic biaryl derivatives |
| 01/15/2004 | WO2003092608A3 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 01/15/2004 | WO2003091247A3 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| 01/15/2004 | WO2003090722A3 Microparticle pharmaceutical compositions for intratumoral delivery |
| 01/15/2004 | WO2003089434A3 IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF |
| 01/15/2004 | WO2003088920A8 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 01/15/2004 | WO2003084936A8 Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological |
| 01/15/2004 | WO2003080118A3 Combination of an aldosterone receptor antagonist and a fibric acid derivative |
| 01/15/2004 | WO2003079969A3 Compositions and methods for treating and preventing necrosis |
| 01/15/2004 | WO2003070905A3 Electroporation methods for introducing bioactive agents into cells |
| 01/15/2004 | WO2003068936A3 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds |
| 01/15/2004 | WO2003064424A3 Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases |
| 01/15/2004 | WO2003062191A8 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 01/15/2004 | WO2003061684A3 Tumour treatment compositions comprising hsp70 and tumour necrosis factor |
| 01/15/2004 | WO2003057148A3 Use of biomolecular targets in the treatment and visualization of tumors |
| 01/15/2004 | WO2003054008A3 Mammalian simp protein, gene sequence and uses thereof in cancer therapy |
| 01/15/2004 | WO2003050271A3 In vitro production of dendritic cells from cd14+ monocytes |
| 01/15/2004 | WO2003049697A3 Treatment of glioblastoma with thymosin-alpha 1 |
| 01/15/2004 | WO2003045307A3 Pharmaceutical formulations comprising indolinone derivatives |
| 01/15/2004 | WO2003041658A3 Process for the preparation of 3,7-disubstituted-2,3,4,5- tetrahydro-1h-1,4-benzodiazepine compounds |
| 01/15/2004 | WO2003039466A3 Method of treating estrogen responsive breast cancer |
| 01/15/2004 | WO2003023048A3 METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l) |
| 01/15/2004 | WO2003019146A3 High throughput screening assays using fatty acid synthetic enzymes |
| 01/15/2004 | WO2003006059A9 Vegfr-1 antibodies to treat breast cancer |
| 01/15/2004 | WO2002096866A3 Thiolalkyl benzoic acid derivatives |
| 01/15/2004 | WO2002092854A3 Genes expressed in breast cancer as prognostic and therapeutic targets |
| 01/15/2004 | WO2002085342A3 Use of nsaids for prevention and treatment of cellular abnormalities of the lung or bronchial pathway |
| 01/15/2004 | WO2002080966A8 Method for producing a vaccine containing autologous antibodies |
| 01/15/2004 | WO2002078526A3 Cancer-testis antigens |
| 01/15/2004 | WO2002072010A3 Taxane prodrugs |